An analysis of the COVID-19 laboratory dataset at AiBST Laboratory in Harare, Zimbabwe, 2020.

Pan Afr Med J

Department of Laboratory Medicine and Investigative Sciences, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.

Published: January 2022

Introduction: coronavirus disease 2019 (COVID-19) has become a major public health problem and has spread rapidly around the globe since its first identification in Wuhan, China, in December 2019. Zimbabwe reported its first case on the 20 March 2020, and since then the disease has spread to almost every part of the country. Laboratory testing is important in controlling this pandemic. However, few studies have focused on assessing trends of SARS-CoV-2 laboratory data. We described SARS-CoV-2 data from African Institute of Biomedical Science and Technology (AiBST) Laboratory in Harare, Zimbabwe.

Methods: a retrospective record review of secondary SARS-CoV-2 data from AiBST Laboratory in Harare between May to September 2020 was done. Epi Info TM 7.2.2.6 was used to generate frequencies, proportions and conduct bivariate analysis.

Results: a total of 6,535 SARS-CoV-2 laboratory records were analysed. The median age of the patients was 36 years and 55% (3594/6535) were males. There was an increase in average analytical turn-around time (TAT) of SARS-CoV-2 results from May to August 2020. Analytical and preanalytical TAT remained above 2 days from August to September. Males were 1.18 times at risk of being SARS-CoV-2 infected than females (p<0.05). The risk of being SARS-CoV-2 infected increased with age from 1.06 in the 11-20 age group to 1.45 in the 41-50 age group.

Conclusion: COVID-19 poses a greater threat to the older age groups and to men. The delayed TAT of SARS-CoV-2 results limits the efforts to control the pandemic. Decentralization of testing to provincial and district level would help improve result TAT.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728806PMC
http://dx.doi.org/10.11604/pamj.2021.40.183.28520DOI Listing

Publication Analysis

Top Keywords

aibst laboratory
12
laboratory harare
12
sars-cov-2 laboratory
8
sars-cov-2 data
8
laboratory
7
sars-cov-2
6
analysis covid-19
4
covid-19 laboratory
4
laboratory dataset
4
dataset aibst
4

Similar Publications

We analyzed parentage data collected over a ten-year period in a Zimbabwean DNA testing laboratory. Parentage case types, prevalence, exclusion data, mutations rates and observed genotyping irregularities were analyzed. We report analysis results from 1303 cases.

View Article and Find Full Text PDF
Article Synopsis
  • Clinical outcomes of tamoxifen (TAM) treatment show high variability among individuals, influenced by genetic differences and other medications.
  • A study involving 229 South African Black women with breast cancer found that certain genetic variants (CYP2D6*17 and CYP2D6*29) significantly impact the metabolism of TAM and its active metabolites.
  • While antiretroviral therapy affected certain metabolite levels of TAM, the overall risk of significant drug interactions was considered low for patients undergoing TAM treatment.
View Article and Find Full Text PDF

An analysis of the COVID-19 laboratory dataset at AiBST Laboratory in Harare, Zimbabwe, 2020.

Pan Afr Med J

January 2022

Department of Laboratory Medicine and Investigative Sciences, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.

Introduction: coronavirus disease 2019 (COVID-19) has become a major public health problem and has spread rapidly around the globe since its first identification in Wuhan, China, in December 2019. Zimbabwe reported its first case on the 20 March 2020, and since then the disease has spread to almost every part of the country. Laboratory testing is important in controlling this pandemic.

View Article and Find Full Text PDF

In this study, we aimed to evaluate the utility of endogenous 1β-hydroxy-deoxycholic acid/total deoxycholic acid ratio (1β-OH-DCA/ToDCA) in spot urine as a surrogate marker of cytochrome P450 3A (CYP3A) activity in the assessment inhibition-based drug-drug interactions in healthy volunteers. This was accomplished through an open-label, three-treatment parallel-arm study in healthy male volunteers from Zimbabwe. Each group received itraconazole (ITZ; 100 mg once daily; = 10), fluconazole (FKZ; 50 mg once daily; = 9), or alprazolam (APZ; 1 mg once daily; = 8) orally.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!